Company Overview

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours.

INOVIQ’s headquarters are based in Melbourne, Australia, and we have representation in the USA with a dedicated team of 20 employees, including 12 R&D members who collectively hold 10 PhDs. Our expertise spans research, development, clinical testing, and commercialisation.

Our Mission

INOVIQ is committed to developing next-generation precision diagnostics and exosome solutions that transform the diagnosis and treatment of cancer and other diseases to improve patient outcomes and save lives.